Modulation of MDR/MRP by wild-type and mutant p53.
Open Access
- 1 March 2001
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 107 (5) , 643-6
- https://doi.org/10.1172/JCI12415
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivoActa Neuropathologica, 2000
- Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cellsJournal of Clinical Investigation, 2000
- Melphalan resistance and photoaffinity labelling of P-glycoprotein in multidrug-resistant Chinese hamster ovary cells: Reversal of resistance by cyclosporin A and hyperthermiaBiochemical Pharmacology, 1999
- `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domainOncogene, 1998
- Wild-type p53-mediated Induction of Rat mdr1bExpression by the Anticancer Drug DaunorubicinJournal of Biological Chemistry, 1998
- Chemosensitivity of human malignant glioma: modulation by p53 gene transferJournal of Neuro-Oncology, 1998
- Involvement of heat shock factor in regulating transcriptional activation of MDR1 gene in multidrug-resistant cellsCancer Letters, 1997
- Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.1995
- The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.1993
- Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53Science, 1992